Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) were up 6.3% on Monday . The company traded as high as $1.46 and last traded at $1.36. Approximately 58,725 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 107,153 shares. The stock had previously closed at $1.28. Analyst […]
Lucid Diagnostics (NASDAQ:LUCD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW […]
Lucid Diagnostics (NASDAQ:LUCD – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in […]
Lucid Diagnostics Inc. (NASDAQ:LUCD – Get Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 736,600 shares, an increase of 37.3% from the April 15th total of 536,300 shares. Based on an average trading volume of 164,700 shares, the short-interest ratio is […]
Lucid Diagnostics (NASDAQ:LUCD – Get Rating) is set to post its quarterly earnings results after the market closes on Wednesday, May 11th. Individual interested in registering for the company’s earnings conference call can do so using this link. Lucid Diagnostics (NASDAQ:LUCD – Get Rating) last issued its quarterly earnings results on Monday, March 28th. The […]